LTC2365972I2 - ATF surišančios kasetės transporterių moduliatoriai - Google Patents

ATF surišančios kasetės transporterių moduliatoriai

Info

Publication number: LTC2365972I2
Authority: LT; Lithuania
Prior art keywords: cartridge conveyor; binding cartridge; modulators; atf binding; atf
Prior art date: 2008-11-06

Application number

Other languages

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-06

Filing date

2019-03-21

Publication date

2019-12-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40933810&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC2365972(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-03-21 Application filed by Vertex Pharma filed Critical Vertex Pharma

2019-04-10 Publication of LTPA2019505I1 publication Critical patent/LTPA2019505I1/lt

2019-12-10 Publication of LTC2365972I2 publication Critical patent/LTC2365972I2/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Neurology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

LTPA2019505 2008-11-06 2019-03-21 ATF surišančios kasetės transporterių moduliatoriai LTC2365972I2 (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11214508P	2008-11-06	2008-11-06
US11215208P	2008-11-06	2008-11-06
PCT/US2008/012689 WO2010053471A1 (en)	2008-11-06	2008-11-12	Modulators of atp-binding cassette transporters

Publications (2)

Publication Number	Publication Date
LTPA2019505I1 LTPA2019505I1 (lt)	2019-04-10
LTC2365972I2 true LTC2365972I2 (lt)	2019-12-10

Family

ID=40933810

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTPA2019505 LTC2365972I2 (lt)	2008-11-06	2019-03-21	ATF surišančios kasetės transporterių moduliatoriai

Country Status (31)

Country	Link
EP (2)	EP2940016A1 (lt)
JP (4)	JP5600322B2 (lt)
KR (3)	KR101587389B1 (lt)
CN (2)	CN108117546A (lt)
AU (1)	AU2008363828B2 (lt)
BR (1)	BRPI0823228B8 (lt)
CA (1)	CA2742821C (lt)
CL (1)	CL2011001027A1 (lt)
CY (2)	CY1116067T1 (lt)
DK (1)	DK2365972T3 (lt)
ES (1)	ES2532753T3 (lt)
FR (1)	FR19C1017I2 (lt)
HK (1)	HK1216526A1 (lt)
HR (1)	HRP20150288T1 (lt)
HU (1)	HUS1900015I1 (lt)
IL (3)	IL212737A (lt)
LT (1)	LTC2365972I2 (lt)
LU (1)	LUC00110I2 (lt)
ME (1)	ME02105B (lt)
MX (2)	MX357497B (lt)
NL (1)	NL300984I9 (lt)
NO (1)	NO2019015I1 (lt)
NZ (2)	NZ609962A (lt)
PL (1)	PL2365972T3 (lt)
PT (1)	PT2365972E (lt)
RS (1)	RS53868B1 (lt)
RU (1)	RU2013157877A (lt)
SI (1)	SI2365972T1 (lt)
UA (1)	UA121188C2 (lt)
WO (1)	WO2010053471A1 (lt)
ZA (1)	ZA201103883B (lt)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX341797B (es)	2004-06-24	2016-09-02	Vertex Pharmaceuticals Incorporated *	Moduladores de transportadores con casete de union con atp.
ES2778846T3 (es)	2005-11-08	2020-08-12	Vertex Pharma	Moduladores heterocíclicos de transportadores de casete de unión a ATP
LT1993360T (lt)	2005-12-28	2017-06-12	Vertex Pharmaceuticals Incorporated	N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
NZ596889A (en)	2006-04-07	2013-06-28	Vertex Pharma	Use of amide indole derivatives as modulators of ATP-binding cassette transporters
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
CN102863432B (zh)	2007-05-09	2016-09-07	沃泰克斯药物股份有限公司	Cftr调节剂
WO2009076142A2 (en)	2007-12-07	2009-06-18	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
KR20150063170A (ko)	2007-12-07	2015-06-08	버텍스 파마슈티칼스 인코포레이티드	3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
CN106432213A (zh)	2008-02-28	2017-02-22	沃泰克斯药物股份有限公司	作为cftr调节剂的杂芳基衍生物
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
UA104876C2 (uk) *	2008-11-06	2014-03-25	Вертекс Фармасьютікалз Інкорпорейтед	Модулятори atф-зв'язувальних касетних транспортерів
HRP20150288T1 (hr) *	2008-11-06	2015-04-24	Vertex Pharmaceuticals Incorporated	Modulatori atp-vezujuä†ih kasetnih transportera
MX384179B (es)	2009-03-20	2025-03-14	Vertex Pharma	Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quística.
SMT202100051T1 (it) *	2010-03-25	2021-03-15	Vertex Pharma	Dispersione solida di una forma amorfa di (r)-1-(2,2-difluorobenzo[d][1,3]diossol-5-il)-n-(1-(2,3-diidrossipropil)-6-fluoro-2-(1-idrossi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropan-carbossamide
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
BR112012026255A2 (pt)	2010-04-07	2017-03-14	Vertex Pharma	composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
RU2745977C2 (ru)	2010-04-22	2021-04-05	Вертекс Фармасьютикалз Инкорпорейтед	Способ получения циклоалкилкарбоксамидо-индольных соединений
AU2011242452A1 (en) *	2010-04-22	2012-11-08	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
WO2011133953A1 (en) *	2010-04-22	2011-10-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
NZ603044A (en) *	2010-04-22	2015-08-28	Vertex Pharma	Pharmaceutical compositions comprising cftr modulators and administrations thereof
JP2013536231A (ja) *	2010-08-23	2013-09-19	バーテックスファーマシューティカルズインコーポレイテッド	（ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与
KR101985044B1 (ko) *	2011-11-08	2019-05-31	버텍스 파마슈티칼스 인코포레이티드	Atp-결합 카세트 수송체의 조절제
DK2806859T3 (da)	2012-01-25	2019-08-05	Vertex Pharma	Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
JP2015511583A (ja)	2012-02-27	2015-04-20	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	薬学的組成物およびその投与
AU2013290444B2 (en)	2012-07-16	2018-04-26	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
WO2014141064A1 (en)	2013-03-13	2014-09-18	Novartis Ag	Notch2 binding molecules for treating respiratory diseases
US9783529B2 (en)	2013-03-13	2017-10-10	Flatley Discovery Lab, Llc	Pyridazinone compounds and methods for the treatment of cystic fibrosis
DK3068392T5 (da)	2013-11-12	2021-09-20	Vertex Pharma	Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
SG10201913575VA (en)	2014-04-15	2020-02-27	Vertex Pharma	Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP2932966A1 (en)	2014-04-16	2015-10-21	Novartis AG	Gamma secretase inhibitors for treating respiratory diseases
SI3142701T1 (en)	2014-05-12	2018-08-31	Verona Pharma Plc	NEW TREATMENT
GB201415381D0 (en)	2014-08-29	2014-10-15	Algipharma As	Inhalable powder formulations of alginate oligomers
EP3798214B1 (en)	2014-10-06	2022-09-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP3204358B1 (en)	2014-10-07	2018-09-19	Vertex Pharmaceuticals Incorporated	Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
WO2016081556A1 (en)	2014-11-18	2016-05-26	Vertex Pharmaceuticals Incorporated	Process of conducting high throughput testing high performance liquid chromatography
EP3240539A4 (en)	2014-12-31	2018-07-25	Auspex Pharmaceuticals, Inc.	Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator
GB201504878D0 (en)	2015-03-23	2015-05-06	Algipharma As	Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
WO2016160945A1 (en)	2015-03-31	2016-10-06	Concert Pharmaceuticals, Inc.	Deuterated vx-661
CN105153106B (zh) *	2015-09-02	2017-08-25	阜新奥瑞凯新材料有限公司	一种2,2‑二氟胡椒酸甲酯的制备方法
GB201517639D0 (en)	2015-10-06	2015-11-18	Algipharma As	Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
US10047077B2 (en)	2016-04-13	2018-08-14	Skyline Antiinfectives, Inc.	Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
JP6601365B2 (ja)	2016-07-27	2019-11-06	株式会社デンソー	制御システム
SG10201913595YA (en)	2016-09-30	2020-02-27	Vertex Pharma	Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
MA49235B1 (fr)	2016-12-09	2021-02-26	Vertex Pharma	Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
EP3634402B1 (en)	2017-06-08	2026-01-21	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
BR112020000941A2 (pt)	2017-07-17	2020-07-21	Vertex Pharmaceuticals Incorporated	métodos de tratamento para fibrose cística
TWI799435B (zh)	2017-08-02	2023-04-21	美商維泰克斯製藥公司	製備化合物之製程
US10988454B2 (en) *	2017-09-14	2021-04-27	Abbvie Overseas S.À.R.L.	Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
IL273831B2 (en)	2017-10-19	2024-10-01	Vertex Pharma	Crystalline forms and compositions of cftr modulators
CN111757874B (zh)	2017-12-08	2024-03-08	弗特克斯药品有限公司	用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
EP3752510B1 (en)	2018-02-15	2022-12-07	Vertex Pharmaceuticals Incorporated	Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
US11414439B2 (en)	2018-04-13	2022-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN111763198B (zh) *	2019-04-01	2021-09-07	新发药业有限公司	一种5-取代环丙基甲酰氨基吲哚衍生物的制备方法
TWI848092B (zh)	2019-04-03	2024-07-11	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白調節劑
KR20220064366A (ko)	2019-08-14	2022-05-18	버텍스 파마슈티칼스 인코포레이티드	Cftr 조절제의 결정질 형태
TWI867024B (zh)	2019-08-14	2024-12-21	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
MX2022001827A (es)	2019-08-14	2022-06-09	Vertex Pharma	Moduladores del regulador de conductancia transmembrana de la fibrosis quistica.
TWI899097B (zh)	2019-08-14	2025-10-01	美商維泰克斯製藥公司	製備cftr調節劑之方法
EP4099991A4 (en)	2020-02-05	2024-06-26	Laurus Labs Limited	NOVEL METHODS FOR THE PRODUCTION OF TEZACAFTOR
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CA3188787A1 (en)	2020-08-13	2022-02-17	Vertex Pharmaceuticals Incorporated	Crystalline forms of cftr modulators
EP3970718A1 (en)	2020-09-18	2022-03-23	Charité - Universitätsmedizin Berlin	New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators
CN116670143A (zh)	2020-10-07	2023-08-29	弗特克斯药品有限公司	囊性纤维化跨膜传导调控因子的调节剂
EP4225737A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076618A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225748A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
TW202233635A (zh)	2020-10-07	2022-09-01	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
EP4225750A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230382924A1 (en)	2020-10-07	2023-11-30	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076626A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CR20230198A (es)	2020-10-07	2023-07-03	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US20230374038A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US12324802B2 (en)	2020-11-18	2025-06-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CA3204725A1 (en)	2020-12-10	2022-06-16	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
KR20240155228A (ko)	2022-02-03	2024-10-28	버텍스 파마슈티칼스 인코포레이티드	(6a,12a)-17-아미노-12-메틸-6,15-비스(트리플루오로메틸)-13,19-디옥사-3,4,18-트리아자트리시클로[12.3.1.12,5]노나데카-1(18),2,4,14,16-펜타엔-6-올의 결정질 형태를 제조하는 방법
JP2025506382A (ja)	2022-02-03	2025-03-11	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症の治療方法
AU2023218262A1 (en)	2022-02-08	2024-08-22	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
KR20250008540A (ko)	2022-04-06	2025-01-14	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막관통 전도도 조절자의 조절제
CA3253026A1 (en)	2022-05-16	2023-11-23	Vertex Pharmaceuticals Incorporated	TREATMENT METHODS FOR CYSTIC FIBROSIS
US20250340568A1 (en)	2022-05-16	2025-11-06	Vertex Pharmaceuticals Incorporated	Solid forms of a macrocyclic compounds as cftr modulators and their preparation
WO2024246174A1 (en)	2023-05-31	2024-12-05	Química Sintética, S.A.	Amorphous and crystalline form of ozanimod hydrochloride
WO2025076240A1 (en)	2023-10-04	2025-04-10	Vertex Pharmaceuticals Incorporated	Solid forms of modulators of cystic fibrosis transmembrane conductance regulator
WO2025076235A1 (en)	2023-10-04	2025-04-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5886026A (en)	1993-07-19	1999-03-23	Angiotech Pharmaceuticals Inc.	Anti-angiogenic compositions and methods of use
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
MX341797B (es)	2004-06-24	2016-09-02	Vertex Pharmaceuticals Incorporated *	Moduladores de transportadores con casete de union con atp.
NZ596889A (en) *	2006-04-07	2013-06-28	Vertex Pharma	Use of amide indole derivatives as modulators of ATP-binding cassette transporters
UA104876C2 (uk)	2008-11-06	2014-03-25	Вертекс Фармасьютікалз Інкорпорейтед	Модулятори atф-зв'язувальних касетних транспортерів
HRP20150288T1 (hr) *	2008-11-06	2015-04-24	Vertex Pharmaceuticals Incorporated	Modulatori atp-vezujuä†ih kasetnih transportera

2008
- 2008-11-12 HR HRP20150288TT patent/HRP20150288T1/hr unknown
- 2008-11-12 CN CN201711204617.5A patent/CN108117546A/zh active Pending
- 2008-11-12 ES ES08876364.4T patent/ES2532753T3/es active Active
- 2008-11-12 UA UAA201312737A patent/UA121188C2/uk unknown
- 2008-11-12 JP JP2011535544A patent/JP5600322B2/ja active Active
- 2008-11-12 BR BRPI0823228A patent/BRPI0823228B8/pt active IP Right Grant
- 2008-11-12 KR KR1020157006518A patent/KR101587389B1/ko active Active
- 2008-11-12 PL PL08876364T patent/PL2365972T3/pl unknown
- 2008-11-12 PT PT08876364T patent/PT2365972E/pt unknown
- 2008-11-12 WO PCT/US2008/012689 patent/WO2010053471A1/en not_active Ceased
- 2008-11-12 DK DK08876364.4T patent/DK2365972T3/en active
- 2008-11-12 NZ NZ609962A patent/NZ609962A/en unknown
- 2008-11-12 ME MEP-2015-37A patent/ME02105B/me unknown
- 2008-11-12 NZ NZ592694A patent/NZ592694A/xx not_active IP Right Cessation
- 2008-11-12 RS RS20150170A patent/RS53868B1/sr unknown
- 2008-11-12 KR KR1020167000956A patent/KR20160013251A/ko not_active Ceased
- 2008-11-12 CA CA2742821A patent/CA2742821C/en active Active
- 2008-11-12 KR KR1020117012764A patent/KR101559963B1/ko active Active
- 2008-11-12 CN CN2008801326311A patent/CN102272127A/zh active Pending
- 2008-11-12 EP EP14197820.5A patent/EP2940016A1/en not_active Withdrawn
- 2008-11-12 MX MX2013012665A patent/MX357497B/es unknown
- 2008-11-12 AU AU2008363828A patent/AU2008363828B2/en active Active
- 2008-11-12 MX MX2011004832A patent/MX2011004832A/es active IP Right Grant
- 2008-11-12 SI SI200831394T patent/SI2365972T1/sl unknown
- 2008-11-12 EP EP08876364.4A patent/EP2365972B1/en active Active
2011
- 2011-05-05 IL IL212737A patent/IL212737A/en active Pre-grant Review Request
- 2011-05-09 CL CL2011001027A patent/CL2011001027A1/es unknown
- 2011-05-26 ZA ZA2011/03883A patent/ZA201103883B/en unknown
2013
- 2013-12-25 RU RU2013157877/04A patent/RU2013157877A/ru not_active Application Discontinuation
2014
- 2014-07-28 IL IL233837A patent/IL233837A/en active IP Right Grant
- 2014-08-15 JP JP2014165547A patent/JP5728611B2/ja active Active
2015
- 2015-03-03 CY CY20151100222T patent/CY1116067T1/el unknown
- 2015-04-06 JP JP2015077925A patent/JP5905620B2/ja active Active
- 2015-06-30 IL IL239713A patent/IL239713A/en active Protection Beyond IP Right Term
2016
- 2016-03-16 JP JP2016052743A patent/JP2016147887A/ja active Pending
- 2016-04-15 HK HK16104342.9A patent/HK1216526A1/en unknown
2019
- 2019-03-13 HU HUS1900015C patent/HUS1900015I1/hu unknown
- 2019-03-15 FR FR19C1017C patent/FR19C1017I2/fr active Active
- 2019-03-21 LT LTPA2019505 patent/LTC2365972I2/lt unknown
- 2019-03-21 LU LU00110C patent/LUC00110I2/fr unknown
- 2019-04-04 NO NO2019015C patent/NO2019015I1/no unknown
- 2019-04-29 NL NL300984C patent/NL300984I9/nl unknown
- 2019-04-30 CY CY2019023C patent/CY2019023I1/el unknown

Also Published As

Publication number	Publication date
IL212737A (en)	2014-08-31
UA121188C2 (uk)	2020-04-27
EP2365972B1 (en)	2014-12-17
CY1116067T1 (el)	2017-02-08
WO2010053471A1 (en)	2010-05-14
DK2365972T3 (en)	2015-01-19
FR19C1017I2 (fr)	2019-07-19
JP2012507580A (ja)	2012-03-29
LUC00110I1 (lt)	2019-03-25
FR19C1017I1 (fr)	2019-05-03
NZ609962A (en)	2014-11-28
CY2019023I2 (el)	2019-11-27
IL239713A0 (en)	2015-08-31
AU2008363828B2 (en)	2016-09-08
BRPI0823228B1 (pt)	2020-10-20
CY2019023I1 (el)	2019-11-27
SI2365972T1 (sl)	2015-04-30
CN102272127A (zh)	2011-12-07
ME02105B (me)	2015-10-20
CN108117546A (zh)	2018-06-05
KR20150036819A (ko)	2015-04-07
AU2008363828A1 (en)	2010-05-14
HK1216526A1 (en)	2016-11-18
KR101559963B1 (ko)	2015-10-26
KR101587389B1 (ko)	2016-01-28
RU2512682C2 (ru)	2014-04-10
CL2011001027A1 (es)	2012-03-02
EP2940016A1 (en)	2015-11-04
CA2742821C (en)	2018-10-23
NL300984I9 (nl)	2019-05-15
CA2742821A1 (en)	2010-05-14
JP5728611B2 (ja)	2015-06-03
WO2010053471A8 (en)	2011-09-22
RS53868B1 (sr)	2015-08-31
HUS1900015I1 (hu)	2019-05-28
MX357497B (es)	2018-07-11
NL300984I2 (nl)	2019-05-02
EP2365972A1 (en)	2011-09-21
JP2015127345A (ja)	2015-07-09
ES2532753T3 (es)	2015-03-31
HK1162477A1 (en)	2012-08-31
JP2014208719A (ja)	2014-11-06
PL2365972T3 (pl)	2015-05-29
JP2016147887A (ja)	2016-08-18
BRPI0823228B8 (pt)	2021-05-25
RU2011122461A (ru)	2012-12-20
RU2013157877A (ru)	2015-06-27
MX2011004832A (es)	2011-07-28
IL212737A0 (en)	2011-07-31
LTPA2019505I1 (lt)	2019-04-10
HRP20150288T1 (hr)	2015-04-24
JP5600322B2 (ja)	2014-10-01
IL233837A (en)	2015-07-30
IL239713A (en)	2017-10-31
JP5905620B2 (ja)	2016-04-20
IL233837A0 (en)	2014-09-30
KR20110082188A (ko)	2011-07-18
KR20160013251A (ko)	2016-02-03
NZ592694A (en)	2013-05-31
ZA201103883B (en)	2012-02-29
PT2365972E (pt)	2015-03-31
BRPI0823228A2 (pt)	2016-10-11
NO2019015I1 (no)	2019-04-04
LUC00110I2 (lt)	2020-07-10

Publication	Publication Date	Title
LTC2365972I2 (lt)	2019-12-10	ATF surišančios kasetės transporterių moduliatoriai
LTPA2015028I1 (lt)	2015-08-25	ATF surišančios kasetės transporterių moduliatoriai
BRPI0813653A2 (pt)	2014-12-30	Compostos de imidazotiazol moduladores de sirtuína
BRPI0813651A2 (pt)	2014-12-30	Compostos de tiazolopiridina moduladores de sirtuína
BRPI0909345A2 (pt)	2017-08-22	aplicador de cartucho de seringa
ZA201005600B (en)	2016-09-28	Ampk modulators
BRPI0917394A2 (pt)	2019-09-24	moduladores de mif
DK2266521T3 (da)	2013-10-28	Plastikampul
BRPI0815075A2 (pt)	2015-02-03	Aglutinantes
BRPI0918734A2 (pt)	2015-12-01	material polimérico
UA19086S (uk)	2009-06-25	Чорнильний картридж
DE602008003191D1 (de)	2010-12-09	Tintenkartuschen
BRPI0816512A2 (pt)	2015-03-24	Cartucho de tinta
BRPI0817149A2 (pt)	2015-03-31	Cartucho de tinta
BRPI0818899A2 (pt)	2015-05-12	Paleta de carga
FI20080181A0 (fi)	2008-03-04	Laippakäämitys
BRPI0810195A2 (pt)	2014-12-30	Moduladores de gpbar1
GB0808886D0 (en)	2008-06-25	Dual purpose modulator
BRPI0913514A2 (pt)	2019-09-24	regeneração pancreática induzida por periostina
IL212534A0 (en)	2011-06-30	Drive cartridge
AT506422A3 (de)	2010-06-15	Snowboardbindung
BRPI0818773A2 (pt)	2015-04-14	Moduladores de gama-secretase ligados a carbono
EP2244262A4 (en)	2012-11-07	PLATE TRAY
IL206612A0 (en)	2010-12-30	Novel imidazolinylmethyl aryl sulfonamides
DE602008002549D1 (de)	2010-10-28	Tintenpatrone